Lung Cancer | Topics

 
Study Results Appear to Support Larotrectinib Use in NTRK+ Lung Cancer
February 20, 2021

Patients with advanced lung cancer whose tumors harbor an NTRK gene fusion with or without central nervous system metastases were found to have high response rates, durable responses, and extended survival benefit with larotrectinib.

Further Patient Education by Clinicians Is Necessary to Facilitate Better Decision Making
January 28, 2021

“With recent advances in early detection of lung cancer, biomarker testing, and personalized treatment planning, effective patient-provider communication is more important than ever for short- and long-term survivorship,” said Kelly Clark, MA.